News

Healio15d
Dyspnea, respiratory drive lower with high-flow nasal therapy in orally intubated patients - Healio
SAN FRANCISCO — Both dyspnea and respiratory drive went down with vs. without nasal high-flow therapy in orally intubated patients, according to research presented at the American Thoracic ...
MedPage Today15d
FDA Approves Once-Monthly Hereditary Angioedema Drug
As previously reported at the annual meeting of the American Academy of Allergy, Asthma & Immunology and published in The Lancet in 2023, garadacimab reduced investigator-confirmed HAE attacks by ...
Channel NewsAsia Singapore15d
Singapore launches national genetic testing programme for hereditary cholesterol condition
SINGAPORE: Singapore will on Jun 30 start a national genetic testing programme for a hereditary cholesterol condition, the Ministry of Health (MOH) said on Thursday (Jun 19). The programme aims to ...
BioWorld16d
Diagonal Therapeutics’ DIAG-723 designated orphan drug for hereditary hemorrhagic telangiectasia
Diagonal Therapeutics Inc.’s DIAG-723 has been awarded orphan drug designation by the FDA for the treatment of hereditary hemorrhagic telangiectasia (HHT). Additionally, the EMA has provided a ...
BioSpace16d
Diagonal’s First-in-Class Clustering Antibody, DIAG723, Receives Orphan Drug Designation (ODD) from U.S. FDA and an ODD Positive Opinion from EMA for Treatment of Hereditary ...
About Hereditary Hemorrhagic Telangiectasia (HHT) ‍HHT is a rare disease that affects more than 150,000 people in the U.S. and EU, and for which there are currently no approved therapies. In HHT, loss ...
Morningstar17d
Diagonal’s First-in-Class Clustering Antibody, DIAG723, Receives Orphan Drug Designation (ODD) from U.S. FDA and an ODD Positive Opinion from EMA for Treatment of Hereditary ...
About Hereditary Hemorrhagic Telangiectasia (HHT) ‍HHT is a rare disease that affects more than 150,000 people in the U.S. and EU, and for which there are currently no approved therapies.
manilatimes17d
Diagonal's First-in-Class Clustering Antibody, DIAG723, Receives Orphan Drug Designation (ODD) from U.S. FDA and an ODD Positive Opinion from EMA for Treatment of Hereditary ...
WATERTOWN, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company focused on correcting dysregulated signaling with clustering antibodies that address the underlying ...
ahajournals.org17d
TGFβ Superfamily in Pulmonary Vascular Disease: The Role of SMAD4
However, the findings of Lv et al 2 contrast interestingly with those of other reports in which endothelial deletion of Smad4 in mice caused the development of arteriovenous malformations in multiple ...
Monthly Prescribing Reference18d
FDA Approves Andembry for Prophylactic Use in Hereditary Angioedema
The Food and Drug Administration (FDA) has approved Andembry ® (garadacimab-gxii) for prophylactic use to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 ...
Healio22d
Ace the Case: A 31-year-old man, with a history of frequent nosebleeds and iron deficiency, diagnosed with von Willebrand disease - Healio
Key teaching points highlighted in this case include hereditary hemorrhagic telangiectasia (HHT) sign/symptom recognition, standard-of-care diagnostic workup, and an introduction to iron ...
jmg.bmj23d
Updates on diagnostic criteria for hereditary haemorrhagic telangiectasia in the light of whole genome sequencing of ‘gene-negative’ individuals recruited to the 100 000 ...
Hereditary haemorrhagic telangiectasia (HHT) is diagnosed clinically by the Curaçao Criteria of spontaneous recurrent nosebleeds, mucocutaneous telangiectasia at characteristic sites, visceral ...
Raleigh News & Observer26d
Recall: Zicam nasal swabs, Orajel baby swabs can have fungus | Raleigh News & Observer
Zicam Nasal AllClear Swabs, which were discontinued in December, carry UPC No. 732216301656.